Zymeworks (STU:ZA8) Cyclically Adjusted Revenue per Share: €1.74 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:ZA8 Zymeworks Inc STU:ZA8
51 GF Score
Price €23.35
GF Value €22.12
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Zymeworks Cyclically Adjusted Revenue per Share?

Zymeworks STU:ZA8 -3.65% 51 Cyclically Adjusted Revenue per Share is €1.74 as of Jun. 2026. GuruFocus rates STU:ZA8 with a GF Score™ of 51/100 and a GF Value™ of €22.12 (Fairly Valued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Zymeworks's adjusted revenue per share for the three months ended in Jun. 2026 was €0.054. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €1.74 for the trailing ten years ended in Jun. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-09-22), Zymeworks's current stock price is €23.35. Zymeworks's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was €1.74. Zymeworks's Cyclically Adjusted PS Ratio of today is 13.43.

During the past 12 years, the highest Cyclically Adjusted PS Ratio of Zymeworks was 15.44. The lowest was 8.57. And the median was 12.57.


Zymeworks  (STU:ZA8) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Zymeworks's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=23.35/1.738
=13.43

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 12 years, the highest Cyclically Adjusted PS Ratio of Zymeworks was 15.44. The lowest was 8.57. And the median was 12.57.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Zymeworks Cyclically Adjusted Revenue per Share Related Terms


Zymeworks Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Zymeworks's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zymeworks Cyclically Adjusted Revenue per Share Chart

Zymeworks Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 1.49 1.62 1.74

Zymeworks Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.68 1.72 1.71 1.74 1.74

STU:ZA8 vs ZBIO, STOK, AGIO: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Zymeworks's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zymeworks Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zymeworks's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Zymeworks's Cyclically Adjusted PS Ratio falls into.


STU:ZA8
51GF Score
Zymeworks Inc STU:ZA8
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zymeworks Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Zymeworks's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.054/333.9520*333.9520
=0.054

Current CPI (Jun. 2026) = 333.9520.

Zymeworks Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.076 241.428 0.105
201612 0.081 241.432 0.112
201703 0.016 243.801 0.022
201706 0.058 244.955 0.079
201709 0.004 246.819 0.005
201712 1.675 246.524 2.269
201803 0.001 249.554 0.001
201806 0.687 251.989 0.910
201809 0.055 252.439 0.073
201812 0.792 251.233 1.053
201903 0.328 254.202 0.431
201906 0.214 256.143 0.279
201909 0.163 256.759 0.212
201912 0.039 256.974 0.051
202003 0.154 258.115 0.199
202006 0.221 257.797 0.286
202009 0.044 260.280 0.056
202012 0.257 260.474 0.329
202103 0.010 264.877 0.013
202106 0.029 271.696 0.036
202109 0.072 274.310 0.088
202112 0.373 278.802 0.447
202203 0.028 287.504 0.033
202206 0.077 296.311 0.087
202209 0.039 296.808 0.044
202212 5.931 296.797 6.673
202303 0.497 301.836 0.550
202306 0.096 305.109 0.105
202309 0.215 307.789 0.233
202312 0.222 306.746 0.242
202403 0.121 312.332 0.129
202406 0.234 314.175 0.249
202409 0.191 315.301 0.202
202412 0.390 315.605 0.413
202503 0.342 319.799 0.357
202506 0.556 322.561 0.576
202509 0.312 324.800 0.321
202512 0.029 324.054 0.030
202603 0.028 330.213 0.028
202606 0.054 333.952 0.054

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €1.74 mean?
Zymeworks (STU:ZA8) has a Cyclically Adjusted Revenue per Share of €1.74 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Zymeworks and its competitors.
Is Zymeworks' Cyclically Adjusted Revenue per Share too high?
Zymeworks' current Cyclically Adjusted Revenue per Share is €1.74. Overall, Zymeworks has a GF Score™ of 51/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Zymeworks' Cyclically Adjusted Revenue per Share compare to ZBIO and STOK?
Zymeworks' Cyclically Adjusted Revenue per Share of €1.74 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Zymeworks and its competitors. Zymeworks's current Cyclically Adjusted Revenue per Share is €1.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zymeworks stock overvalued right now?
Based on GuruFocus' analysis, Zymeworks (STU:ZA8) is currently considered Fairly Valued. The stock's GF Value™ is €22.12, compared to a current price of €23.35 — trading 5.6% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is €1.74. Zymeworks' overall GF Score™ is 51/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Zymeworks (STU:ZA8), the current Cyclically Adjusted Revenue per Share is €1.74 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zymeworks (STU:ZA8) Overvalued in 2026?

Based on GuruFocus' analysis, Zymeworks stock appears to be overvalued. The current stock price of €23.35 is trading 5.6% above its estimated GF Value™ of €22.12. GuruFocus considers Zymeworks to be Fairly Valued.

Key valuation signals for STU:ZA8:

  • Cyclically Adjusted Revenue per Share: €1.74
  • GF Value™: €22.12 vs. price of €23.35 (5.6% above fair value)
  • GF Score™: 51/100 with 4 warning signs

No single metric tells the full story. See the STU:ZA8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Zymeworks Business Description

Other Exchanges ZYME:USA
Address 108 Patriot Drive, Suite A, Middletown, DE, USA, 19709
Zymeworks Inc. is a clinical-stage biopharmaceutical company that discovers, develops, and commercializes multifunctional biotherapeutics, primarily for cancer. Its lead candidate, zanidatamab, is a HER2-targeted bispecific antibody being developed for solid tumors that express HER2, including biliary tract and gastroesophageal cancers. The company also advances earlier-stage oncology programs and antibody-drug conjugate candidates built on its proprietary engineering platforms, such as Azymetric and EFECT. Zymeworks operates a fully integrated drug development engine spanning discovery through clinical development. It generates revenue through collaboration and licensing agreements with pharmaceutical partners, including BeiGene and Jazz Pharmaceuticals, which hold development and commercialization rights in certain territories, as well as through milestone payments and royalties. The company is headquartered in Vancouver, Canada, with operations in the United States, and its shares trade on the Nasdaq under the ticker ZYME.
51GF Score

Get the complete analysis for STU:ZA8

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€23.35
Price
€22.12
GF Value